Biodesix, Boulder, Colo, has recently presented new data demonstrating that the company’s VeriStrat test is predictive of outcomes for patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors in the frontline setting, even when adjusted for PD-L1 status.1,2
The VeriStrat test is a multivariate, mass-spectrometry based test that measures circulating proteins in the blood, serum, or plasma of patients with NSCLC. Test results assign a good or poor classification to patient samples. Multiple studies support the observation that patients with a good result have a better prognosis than patients with a poor result, independent of current clinical prognostic indicators and treatment choice. VeriStrat testing has been validated in more than 70 studies with more than 6,600 patients, and is covered by Medicare and most private health insurers.
The presented data were part of an interim analysis from a prospectively designed observational study, which is currently enrolling NSCLC patients at 33 sites in the United States and will follow patient outcomes for 18 months. The preplanned interim analysis was conducted with the first 1,000 patients enrolled with at least a 12-month follow-up.
Results for the subset of patients with advanced NSCLC treated with frontline immune checkpoint inhibitors, with or without chemotherapy (n = 85; all frontline therapies n = 419), suggest that incorporating the host immune response as part of the initial patient assessment provides clinically meaningful information when choosing a frontline therapy for NSCLC.
Immune checkpoint inhibitors have emerged as standard treatment for wild-type patients with NSCLC based on established superiority of efficacy over chemotherapy. However, it is known that not all patients testing positive for PD-L1 respond to immune checkpoint inhibitors.
Biodesix is a lung cancer diagnostic company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with non-small cell lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ nodule test, which will be commercially available in the second half of 2019, evaluates the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world’s leading biotechnology and pharmaceutical companies to develop companion diagnostics. For more information about Biodesix, please visit www.biodesix.com.
Kena Hudson for Biodesix